GLP-1 patches do not work the same way as prescription injectable GLP-1 medications
The name itself, SMGT-GLP-1, is designed to make you think you are getting actual GLP-1 technology
Ongoing research is focused on multi-target agonists, oral drugs, and broader therapeutic applications beyond diabetes and obesity, including cardiovascular, kidney, liver, and neurodegenerative conditions
Why are so many denials reversed on appeal
Reducing the recruitment of -arrestin and the residence time of the ligand towards the receptor, thus decreasing internalization, is presumably the key of incretin drugs
This was despite the fact that the work behind the patent, filed in 1997 and granted in 2001, demonstrated that the peptide helped to lower body weight for four weeks in type 2 diabetes patients who were obese (DiMarchi, Efendic)